Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 12Kidney Neoplasms 5Neoplasms 3Neoplasm Metastasis 2Skin Neoplasms 1Radiation Therapy 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 6cemiplimab 4aldesleukin 3Interleukin-2 3fludarabine 2Specimen Handling 2Niacinamide 2HhAntag691 2Cyclophosphamide 2Blood Specimen Collection 2Biopsy 2trametinib 1spartalizumab 1sonidegib 1pertuzumab 1lifileucel 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1dabrafenib 1brodalumab 1atezolizumab 1Vitamin A 1Trastuzumab 1Tissue Banks 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1Second Harmonic Generation Microscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Skin Neoplasms × Axitinib × Clear all
NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
25 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡